TyrNovo

Company Overview

Snapshot

Founded in September 2013, TyrNovo operates with 1–10 employees. The company was acquired by Purple Biotech in January 2017, marking a significant milestone in its trajectory.

Business overview

TyrNovo is a Health Tech & Life Sciences company focused on developing cancer treatments that prevent drug resistance and enhance life expectancy. The company's core technology involves promoting the degradation of insulin-receptor substrates 1 and 2, utilizing compounds like NT157 and NT219 to extensively block major oncogenic pathways. TyrNovo operates within the Pharmaceuticals sector, specifically targeting drug discovery and development in oncology.

Strategic signal

In January 2017, TyrNovo was acquired by Purple Biotech, signaling a strategic move for Purple Biotech to enter the immuno-oncology field. This acquisition integrated TyrNovo's activities, including its novel compounds NT157 and NT219, into Kitov Pharmaceuticals (now Purple Biotech), indicating a validation of TyrNovo's targeted therapy approach and its potential to improve cancer treatment.

Company Intelligence Q&A

What was a significant corporate event for TyrNovo?

TyrNovo was acquired by Purple Biotech in January 2017. This acquisition integrated TyrNovo's activities into Kitov Pharmaceuticals, expanding their focus into the immuno-oncology field.

When was TyrNovo founded?

TyrNovo was founded in September 2013.

What is TyrNovo's primary focus in cancer treatment?

TyrNovo focuses on developing targeted therapies to prevent resistance to cancer drugs by eliminating key proteins and activating the 'off switch' for major oncogenic pathways.

Which compounds are central to TyrNovo's technology?

TyrNovo's technology is centered around the compounds NT157 and NT219, which were exclusively licensed from Yissum Research Development Company of the Hebrew University of Jerusalem.

What is the employee count for TyrNovo?

TyrNovo operates with 1–10 employees.